https://lapp.nl/ 2024-09-09 https://lapp.nl/pharmacometric-science/presentations/ 2024-06-04 https://lapp.nl/pharmacometric-science/publications/ 2023-12-07 https://lapp.nl/team/ 2026-03-11 https://lapp.nl/software/ 2023-06-21 https://lapp.nl/pharmacometric-models/ 2023-06-13 https://lapp.nl/contact/ 2026-01-07 https://lapp.nl/experience/ 2022-07-19 https://lapp.nl/pharmacometric-science/ 2024-06-04 https://lapp.nl/pharmacometric-services/ 2022-07-19 https://lapp.nl/company/ 2023-06-13 https://lapp.nl/integrated-pk-pd-model-relating-serum-copper-concentrations-urinary-copper-clearance-and-trientine-pharmacokinetics-in-wilson-disease-initial-insights-from-the-united-study-2/ 2025-12-05 https://lapp.nl/causal-mediation-analysis-in-a-pharmacometrics-context-2/ 2025-12-05 https://lapp.nl/performance-of-neural-ordinary-differential-equations-in-a-multiple-dose-pharmacometrics-setting-2/ 2025-12-05 https://lapp.nl/a-modellers-perspective-on-em-methods-versus-foce-in-nonmem-2/ 2025-12-05 https://lapp.nl/repeated-time-to-event-modelling-of-morphine-pharmacodynamics-for-analgesia-after-paediatric-cardiac-surgery-2/ 2025-12-05 https://lapp.nl/favorable-pharmacokinetic-characteristics-of-extended-half-life-recombinant-factor-viii-bay-94-9027-enable-robust-individual-profiling-using-a-population-pharmacokinetic-approach/ 2025-12-05 https://lapp.nl/translation-from-animal-to-clinical-studies-choosing-the-optimal-moment-comment/ 2025-12-05 https://lapp.nl/model-informed-drug-development-for-daprodustat-supports-the-design-of-individualized-dosing-regimens-in-chronic-kidney-disease-patients-with-anemia/ 2025-12-05 https://lapp.nl/population-pharmacokinetics-of-asundexian-in-people-at-risk-for-thromboembolic-cardiovascular-events/ 2025-12-05 https://lapp.nl/a-novel-maturation-equation-for-hepatic-clearance-across-preterm-term-neonateschildren-and-adults-application-toparacetamol-and-its-metabolite/ 2025-12-05 https://lapp.nl/from-in-vitro-efficacy-to-long-term-hba1c-response-for-glp-1r-glucagonr-agonism-using-the-4gi-hba1c-systems-model-2/ 2025-12-05 https://lapp.nl/translational-minimal-physiologically-based-pharmacokinetic-model-for-transferrin-receptor-mediated-brain-delivery-of-antibodies/ 2025-12-05 https://lapp.nl/safety-tolerability-and-pharmacokinetics-of-the-neuroprotectant-2-iminobiotin-in-patients-with-large-vessel-occlusion-ischemic-stroke-treated-with-endovascular-thrombectomy/ 2025-12-05 https://lapp.nl/development-of-a-ribavirin-dosing-regimen-in-transplant-recipients-with-chronic-hepatitis-e-virus-infection-a-population-pharmacokinetic-and-dynamic-model/ 2025-12-05 https://lapp.nl/integrated-pk-pd-model-relating-serum-copper-concentrations-urinary-copper-clearance-and-trientine-pharmacokinetics-in-wilson-disease-initial-insights-from-the-united-study/ 2025-06-18 https://lapp.nl/causal-mediation-analysis-in-a-pharmacometrics-context/ 2025-06-18 https://lapp.nl/performance-of-neural-ordinary-differential-equations-in-a-multiple-dose-pharmacometrics-setting/ 2025-06-18 https://lapp.nl/a-modellers-perspective-on-em-methods-versus-foce-in-nonmem/ 2025-06-18 https://lapp.nl/repeated-time-to-event-modelling-of-morphine-pharmacodynamics-for-analgesia-after-paediatric-cardiac-surgery/ 2025-06-18 https://lapp.nl/overadjustment-bias-and-mediation-analysis-in-pk-pd-modeling/ 2025-06-18 https://lapp.nl/the-drug-titration-paradox-in-the-presence-of-intra%e2%80%91individual-variation-can-we-estimate-the-true-concentration%e2%80%91effect-relationship/ 2025-06-18 https://lapp.nl/drug-release-from-docetaxel-entrapped-core-crosslinked-polymeric-micelles-a-population-pharmacokinetic-modelling-approach-based-on-clinical-data/ 2025-06-18 https://lapp.nl/defining-preclinical-efficacy-with-the-dnapk-inhibitor-azd7648-in-combination-with-olaparib-a-minimal-systems-pharmacokinetic-pharmacodynamic-model/ 2025-06-18 https://lapp.nl/tutorial-on-conditional-simulations-with-a-tumor-size-overall-survival-model-to-support-oncology-drug-development/ 2025-06-18 https://lapp.nl/development-of-a-joint-tumor-size-overall-survival-modeling-and-simulation-framework-supporting-oncology-development-decision-making/ 2025-06-18 https://lapp.nl/effects-of-efgartigimod-treatment-on-humoral-and-cellular-immune-responses-analysis-of-t-cell-dependent-antibody-response-in-cynomolgus-monkeys/ 2025-06-18 https://lapp.nl/translational-population-target-binding-model-for-the-anti-fcrn-fragment-antibody-efgartigimod/ 2025-06-12 https://lapp.nl/time-varying-covariates-overadjustment-bias-and-mediation-in-pharmacokinetic-pharmacodynamic-modeling/ 2025-06-12 https://lapp.nl/in-memoriam-lambertus-bert-a-peletier-29-march-1937-16-december-2023-furthering-quantitative-pharmacology-through-applied-mathematics/ 2025-06-12 https://lapp.nl/integrated-population-pharmacokinetics-of-daprodustat-in-patients-with-chronic-kidney-disease-with-anemia/ 2025-06-12 https://lapp.nl/a-model-based-approach-using-gsk3772847an-anti-interleukin-33-receptor-monoclonal-antibodyas-a-showcase-to-predict-sc-administration-pk-andfree-target-dynamics-based-on-pk-and-total-targetmeasureme/ 2025-06-12 https://lapp.nl/user-friendly-parameter-identifiability-methods-with-a-workflow-to-guide-model-development-using-categorical-and-continuous-scales/ 2024-07-05 https://lapp.nl/population-analysis-of-mg-adl-total-score-for-efgartigimod-phase-3-study-in-myasthenia-gravis-patients-application-of-a-bounded-integer-model/ 2024-07-05 https://lapp.nl/a-population-pk-analysis-of-docetaxel-after-iv-administration-of-cpc634-cripec-docetaxel-and-generic-docetaxel-in-plasma-and-tumor/ 2024-07-05 https://lapp.nl/the-effect-of-ph-on-intratumoural-docetaxel-release-from-polymeric-nanoparticle-cpc634/ 2024-07-05 https://lapp.nl/from-in-vitro-efficacy-to-long-term-hba1c-response-for-glp-1r-glucagonr-agonism-using-the-4gi-hba1c-systems-model/ 2024-07-05 https://lapp.nl/case-study-of-exposure-safety-analysis-in-phase-1-oncology-lessons-learned/ 2024-07-05 https://lapp.nl/the-drug-titration-paradox-in-the-presence-of-intra-individual-variation-can-we-estimate-the-true-concentration-effect-relationship/ 2024-07-05 https://lapp.nl/time-varying-covariates-mediation-analysis-and-overadjustment-bias-in-pk-pd-modelling/ 2024-07-05 https://lapp.nl/novel-maturation-function-to-capture-the-maturation-of-hepatic-clearance-in-preterm-and-term-neonates-to-older-infants-children-and-adults-application-to-paracetamol-and-metabolites-pk/ 2024-07-05 https://lapp.nl/belimumab-pharmacokinetic-simulations-to-select-an-appropriate-subcutaneous-dosing-regimen-to-treat-paediatric-patients-with-active-lupus-nephritis/ 2024-07-05 https://lapp.nl/a-model-based-approach-to-predict-sc-administration-and-free-target-dynamics-for-monoclonal-antibodies-using-pk-and-total-target-measurements-after-iv-administration/ 2024-07-05 https://lapp.nl/characterisation-of-cotadutides-dual-glp-1-glucagon-receptor-agonistic-effects-on-glycaemic-control-using-an-in-vivo-human-glucose-regulation-quantitative-systems-pharmacology-model/ 2024-07-05 https://lapp.nl/application-of-quantitative-protein-mass-spectrometric-data-in-the-early-predictive-analysis-of-membrane-bound-target-engagement-by-monoclonal-antibodies/ 2024-07-05 https://lapp.nl/navigating-the-landscape-of-parameter-identifiability-methods-a-workflow-recommendation-for-model-development/ 2024-07-05 https://lapp.nl/when-will-the-glomerular-filtration-rate-in-former-preterm-neonates-catch-up-with-their-term-peers/ 2024-07-05 https://lapp.nl/two-new-user-friendly-methods-to-assess-pharmacometric-parameter-identifiability-on-categorical-and-continuous-scales/ 2024-07-05 https://lapp.nl/quantification-of-the-effect-of-glp-1r-agonists-on-body-weight-using-in-vitro-efficacy-information/ 2024-07-05 https://lapp.nl/neuroprotection-after-cardiac-arrest-with-2-iminobiotin/ 2024-06-04 https://lapp.nl/advances-in-pharmacokinetic-pharmacodynamic-modelling-for-pediatric-drug-development/ 2024-06-04 https://lapp.nl/pharmacokinetics-and-pharmacodynamics-of-finerenone-in-patients-with-chronic-kidney-disease/ 2024-06-04 https://lapp.nl/population-pharmacokinetics-of-jesduvroq-daprodustat-in-chronic-kidney-disease-patients-with-anemia/ 2023-09-27 https://lapp.nl/innovative-adaptive-dose-simulations-in-nonmem-to-allow-simulation-based-model-evaluation-of-titration-based-dosing-applied-to-a-population-dose-hemoglobin-model-for-jesduvroq-daprodustat/ 2023-09-27 https://lapp.nl/two-new-user-friendly-approaches-to-assess-pharmacometric-model-identifiability/ 2023-12-07 https://lapp.nl/linking-4gi-glucose-homeostasis-and-hall-body-composition-models-to-study-glp-1r-agonist-effects-on-glucose-and-body-weight/ 2023-09-27 https://lapp.nl/population-pk-pd-analysis-for-efgartigimod-phase-3-study-in-myasthenia-gravis-patients/ 2023-09-27 https://lapp.nl/development-of-a-joint-tumor-size-ts%e2%88%92overall-survival-os-modeling-and-simulation-ms-framework-supporting-oncology-development-decision-making/ 2023-09-27 https://lapp.nl/conditional-overall-survival-os-simulations-with-a-joint-tumor-size-ts-os-model-to-support-oncology-development-decision-making/ 2023-09-27 https://lapp.nl/from-glomerular-filtration-rate-to-renal-composite-endpoint-an-integrated-time-to-event-analysis-of-finerenone-in-phase-3-studies/ 2023-09-27 https://lapp.nl/population-dose-hgb-modelling-of-jesduvroq-daprodustat-across-five-phase-3-studies-in-chronic-kidney-disease-patients-with-anemia/ 2023-09-27 https://lapp.nl/building-an-adaptive-dose-simulation-framework-to-aid-dose-and-schedule-selection/ 2023-11-21 https://lapp.nl/longitudinal-efficacy-and-safety-modeling-and-simulation-framework-to-aid-dose-selection-of-belantamab-mafodotin-for-patients-with-multiple-myelo/ 2024-06-04 https://lapp.nl/extended-use-of-levonorgestrel-releasing-intrauterine-system-lng-ius-52-mg-a-population-pharmacokinetic-approach-to-estimate-in-vivo-levonorgestrel-release-rates-and-systemic-exposure-including-com/ 2024-06-04 https://lapp.nl/evaluation-of-a-cardiovascular-systems-model-for-design-and-analysis-of-hemodynamic-safety-studies/ 2023-09-27 https://lapp.nl/population-pharmacokinetics-of-riociguat-in-a-pediatric-population-aged-%e2%89%a5-6-years-with-pulmonary-arterial-hypertension/ 2023-09-27 https://lapp.nl/model-informed-bridging-of-rivaroxaban-doses-for-thromboprophylaxis-in-pediatric-patients-with-congenital-heart-disease-aged-9-years-and-above/ 2024-06-04 https://lapp.nl/a-translational-cardiovascular-systems-model-to-quantify-drug-effects-on-contractility-and-other-hemodynamic-variables/ 2022-11-25 https://lapp.nl/finerenone-dose-exposure-response-for-the-primary-kidney-outcome-in-fidelio-dkd-phase-iii-population-pharmacokinetic-and-time-to-event-analysis/ 2022-11-25 https://lapp.nl/linking-the-4gi-glucose-homeostasis-and-hall-body-composition-models-to-quantify-weight-loss-effects-of-glp-1r-agonists-and-body-weight-effects-on-insulin-sensitivity/ 2022-11-25 https://lapp.nl/population-pharmacokinetics-of-daprodustat-across-five-phase-2b-3-studies-in-chronic-kidney-disease-ckd-patients-with-anemia/ 2022-11-25 https://lapp.nl/population-dose-hgb-modelling-of-daprodustat-across-five-phase-3-studies-in-chronic-kidney-disease-ckd-patients-with-anemia/ 2022-11-25 https://lapp.nl/innovative-adaptive-dose-simulations-in-nonmem-to-allow-simulation-based-model-evaluation-of-titration-based-dosing-applied-to-a-population-doe-hemoglobin-model-for-daprodustat/ 2023-12-07 https://lapp.nl/application-of-quantitative-protein-mass-spectrometric-data-in-the-early-predictive-analysis-of-target-engagement-by-monoclonal-antibodies/ 2022-05-10 https://lapp.nl/a-novel-cardiovascular-systems-model-to-quantify-drugs-effects-on-the-inter-relationship-between-contractility-and-other-hemodynamic-variables/ 2022-05-10 https://lapp.nl/the-effect-of-ibuprofen-exposure-and-patient-characteristics-on-the-closure-of-the-patent-ductus-arteriosus-in-preterm-infants/ 2024-06-04 https://lapp.nl/dose-exposure-response-analysis-of-the-nonsteroidal-mineralocorticoid-receptor-antagonist-finerenone-on-uacr-and-egfr-an-analysis-from-fidelio-dkd/ 2024-06-04 https://lapp.nl/a-novel-integrated-qsp-model-of-in-vivo-human-glucose-regulation-to-support-the-development-of-a-glucagon-glp-1-dual-agonist/ 2022-05-10 https://lapp.nl/pk-pd-modeling-of-fxi-antisense-oligonucleotides-to-bridge-the-dose-fxi-activity-relation-from-healthy-volunteers-to-end-stage-renal-disease-patients/ 2021-11-24 https://lapp.nl/finerenone-dose-exposure-response-for-the-primary-kidney-outcome-in-fidelio-dkd-phase-iii/ 2021-11-24 https://lapp.nl/finerenone-dose-exposure-serum-potassium-response-analysis-of-fidelio-dkd-phase-iii/ 2021-11-24 https://lapp.nl/population-pharmacokinetic-analysis-of-rivaroxaban-in-children-and-comparison-to-prospective-physiologically-based-pharmacokinetic-predictions/ 2021-08-25 https://lapp.nl/successful-prediction-of-continuous-glucose-dynamics-and-hba1c-response/ 2021-08-25 https://lapp.nl/population-dose-response-analysis-of-hemoglobin-data/ 2021-08-25 https://lapp.nl/population-pharmacokinetic-analysis-of-daprodustat-in-healthy-volunteers-hv/ 2021-08-25 https://lapp.nl/population-pharamcokinetic-pharmacodynamics-pkpd-analysis-of-epo-during-daprodustat-treatment-in-healthy-volunteers-hv-and-chronic-kidney-disease-ckd-patients-with-anemia/ 2021-08-25 https://lapp.nl/a-population-k-pd-model-analysis-of-long-term-testosterone-inhibition-in-prostate-cancer-patients-undergoing-intermittent-androgen-deprivation-therapy/ 2021-08-25 https://lapp.nl/understanding-effect-site-pharmacology-of-uprifosbuvir-a-hepatitis-c-virus-nucleoside-inhibitor/ 2021-08-25 https://lapp.nl/a-population-pharmacokinetics-analysis-assessing-the-exposure-of-raltegravir-once%e2%80%90daily-1200mg-in-pregnant-women-living-with-hiv/ 2021-08-25 https://lapp.nl/direct-comparison-of-two-extended-half-life-pegylated-recombinant-fviii-products/ 2021-08-25 https://lapp.nl/population-pharmacokinetic-and-exposure-response-analysis-of-finerenone-2/ 2024-06-04 https://lapp.nl/a-phase-iia-clinical-trial-of-2-%e2%80%91-iminobiotin-for-the-treatment-of-birth-asphyxia-in-dr-congo/ 2024-06-04 https://lapp.nl/pharmacokinetic-and-pharmacodynamic-modeling-of-the-metastin-kisspeptin-analog-tak-448-for-its-anti-tumor-efficacy-in-a-rat-xenograft-model/ 2020-10-02 https://lapp.nl/mechanism-based-modeling-of-the-effect-of-a-novel-inhibitor-of-vascular-adhesion-protein-1-on-albuminuria-and-renal-function-markers-in-patients-with-diabetic-kidney-disease/ 2020-10-02 https://lapp.nl/population-pharmacokinetics-and-pharmacodynamics-of-a-novel-vascular-adhesion-protein-1-inhibitor-using-a-multiple-target-mediated-drug-disposition-model/ 2024-06-04 https://lapp.nl/population-pharmacokinetics-of-regorafenib-in-solid-tumours/ 2020-10-02 https://lapp.nl/performance-of-the-saem-and-focei-algorithms-in-the-open-source-non-linear-mixed-effect-modelling-tool-nlmixr-2/ 2021-01-08 https://lapp.nl/pharmacokinetics-and-short-term-safety-of-the-selective-nos-inhibitor-2-iminobiotin-in-asphyxiated-neonates-treated-with-therapeutic-hypothermia-pediatr/ 2021-02-22 https://lapp.nl/exploration-of-efficacious-alternative-regorafenib-regimens/ 2019-10-20 https://lapp.nl/nonlinear-mixed-effects-model-development-and-simulation/ 2024-06-04 https://lapp.nl/population-pharmacokinetic/ 2024-06-04 https://lapp.nl/exploration-of-alternative-regorafenib-regimens-to-manage-hand-foot-skin-reaction/ 2019-10-18 https://lapp.nl/direct-comparison-of-two-extended-half-life-recombinant-fviii-products/ 2023-11-21 https://lapp.nl/performance-of-the-saem-and-focei-algorithms-in-the-open-source-non-linear-mixed-effect-modelling-tool-nlmixr/ 2024-06-04 https://lapp.nl/tumor-necrosis-factor-mediated-disposition-of-infliximab-in-ulcerative-colitis-patients/ 2024-06-04 https://lapp.nl/favorable-pharmacokinetic-characteristics-of-extended-%e2%80%91-half-%e2%80%91-life-recombinant-factor-viii-bay-94-%e2%80%91-9027/ 2024-06-04 https://lapp.nl/performance-of-the-saem-and-focei-algorithms/ 2019-10-20 https://lapp.nl/population-pharmacokinetic-and-exposure-response-analysis-of-finerenone/ 2024-06-04 https://lapp.nl/a-mechanism-based-population-k-pd-model-for-long-term-testosterone-inhibition-in-prostate-cancer-patients-under-intermittent-androgen-deprivation-therapy/ 2021-01-08 https://lapp.nl/integrate-qsp-model-of-in-vivo-human-glucose-regulation-to-support-development-of-a-glucagon-glp-1-dual-agonist/ 2021-01-08 https://lapp.nl/predicting-the-effect-of-glp-1-agonists-on-glucose-and-hba1c-with-a-4gi-hba1c-modelo/ 2024-06-04 https://lapp.nl/an-integrated-population-pharmacokinetic-analysis/ 2024-06-04 https://lapp.nl/linear-pharmacokinetic-parameters-for-monoclonal-antibodies/ 2023-11-21 https://lapp.nl/application-of-a-mk-3682-minimal-pbpk-pd-model/ 2019-10-18 https://lapp.nl/a-perspective-on-the-state-of-pharmacometrics-and-systems-pharmacology-integration/ 2024-06-04 https://lapp.nl/extending-a-systems-model-of-the-app-pathway/ 2024-06-04 https://lapp.nl/a-project-centric-r-shiny-run-management-tool-for-nlmixr/ 2019-10-18 https://lapp.nl/pharmacokinetic-and-pharmacodynamic-modelling/ 2024-06-04 https://lapp.nl/an-hcv-nucleoside-inhibitor-mk-3682-minimal-pbpk-pd-model/ 2019-10-18 https://lapp.nl/anovel-integrate-qsp-model-of-in-vivo-human-glucose-regulation/ 2019-10-20 https://lapp.nl/35-years-of-modelling-and-simulation/ 2019-10-18 https://lapp.nl/filling-the-gap-between-hypothesis-and-reality/ 2019-10-20 https://lapp.nl/a-perspective-on-integrating-pharmacometrics-and-quantitative-systems-pharmacology-characteristics/ 2019-10-18 https://lapp.nl/application-of-an-ipsp-model/ 2019-10-18 https://lapp.nl/utorial-1-nlmixr-population-modeling-in-r/ 2019-10-18 https://lapp.nl/solving-sensitivity-equations/ 2019-10-20 https://lapp.nl/exploring-inductive-linearization-in-population-pharmacokinetic-and-pharmacodynamic-models/ 2019-10-18 https://lapp.nl/evaluate-the-effect-of-intrinsic-and-extrinsic-factors-on-regorafenib-reg-exposure/ 2019-10-18 https://lapp.nl/frequency-domain-response-analysis/ 2024-06-04 https://lapp.nl/systems-pharmacology-analysis-of-the-a%ce%b2-oligomer-response-following-%ce%b2-secretase-inhibition/ 2019-10-18 https://lapp.nl/influence-of-body-composition/ 2024-06-04 https://lapp.nl/a-systems-pharmacology-approach-unfolds-a%ce%b2-oligomer-modulation/ 2019-10-18 https://lapp.nl/resilience-in-the-amyloid-precursor-protein-app-pathway-revealed/ 2019-10-18 https://lapp.nl/impact-of-acute-fat-mobilisation/ 2024-06-04 https://lapp.nl/a-cross-species-translational-pharmacokinetic-pharmacodynamic-evaluation/ 2024-06-04 https://lapp.nl/population-pharmacokinetic-characterization-of-bay-81-8973/ 2024-06-04 https://lapp.nl/frequency-domain-response-analysis-2/ 2019-10-20 https://lapp.nl/exposure-response-relationship-of-regorafenib-efficacy/ 2024-06-04 https://lapp.nl/optimization-of-trial-design-and-dose-selection-based-on-the-quantitative-assessement-of-the-efficacy-of-tak-385/ 2017-12-28 https://lapp.nl/qsp-modelling-at-the-heart-of-the-action/ 2017-12-28 https://lapp.nl/quantification-of-the-modulation-of-the-a%ce%b2-oligomers-following-secretase-inhibition/ 2017-12-27 https://lapp.nl/quantification-of-the-modulation-of-a%ce%b2-oligomers-following-secretase-inhibition-a-systems-pharmacology-approach/ 2017-12-27 https://lapp.nl/systems-pharmacology-analysis-of-the-amyloid-cascade/ 2024-06-04 https://lapp.nl/design-of-bispecific-monoclonal-antibodies/ 2023-11-21 https://lapp.nl/population-pharmacokinetic-modeling-of-tapentadol-extended-release/ 2024-06-04 https://lapp.nl/characterization-and-prediction-of-cardiovascular-effects-of-fingolimod-and-siponimod/ 2024-06-04 https://lapp.nl/pkpd-modelling-of-the-relationship-between-testosterone-and-psa/ 2017-12-27 https://lapp.nl/a-mechanism-based-model-is-able-to-simultaneously-explain-the-effect-of-rhlcat-and-hdl-mimetics-on-biomarkers-of-reverse-cholesterol-transport/ 2017-12-27 https://lapp.nl/application-of-a-semi-mechanistic-integrated-glucose-insulin-model-to-graded-glucose-infusion-placebo-data/ 2017-12-27 https://lapp.nl/recombinant-antithrombin-atryn-to-achieve-80-at-activity-in-pediatric-and-neonatal-ecmo-patients/ 2025-12-05 https://lapp.nl/application-of-a-systems-pharmacology-based-placebo-population-model/ 2024-06-04 https://lapp.nl/model-based-once-daily-darunavir-ritonavir-dosing-recommendations/ 2024-06-04 https://lapp.nl/dose-selection-of-antithrombin-recombinant/ 2025-12-05 https://lapp.nl/does-it-take-two-or-four-to-tango-modeling-simulation-of-bispecific-antibodies-in-oncology/ 2017-12-27 https://lapp.nl/characterization-and-prediction-of-cardiovascular-effects-of-s1p-receptor-agonists/ 2017-12-27 https://lapp.nl/characterization-and-prediction-of-cardiovascular-effects-of-s1p-receptor-agonists-a-systems-pharmacology-modeling-approach/ 2017-12-27 https://lapp.nl/mechanism-based-pk-pd-model-for-the-effect-of-rhlcat-and-apoa-i-preparations/ 2017-12-27 https://lapp.nl/a-systems-pharmacology-model-accounting-for-tracer-dynamics-throughout-the-app-pathway/ 2017-12-27 https://lapp.nl/integrating-tracer-kinetic-data-with-absolute-protein-concentration-measurements-in-a-systems-pharmacology-model/ 2017-12-27 https://lapp.nl/a-new-model-based-approach-to-compare-toxicity-of-a-series-of-compounds/ 2017-12-27 https://lapp.nl/quantification-of-the-effect-of-azd5213/ 2017-12-27 https://lapp.nl/evaluation-of-the-long-term-durability-and-glycemic-control-of-fasting-plasma-glucose-and-glycosylated-hemoglobin/ 2024-06-04 https://lapp.nl/translational-pharmacokinetic-modeling-of-fingolimod/ 2024-06-04 https://lapp.nl/drug-effects-on-the-cardiovascular-system-in-conscious-rats/ 2024-06-04 https://lapp.nl/a-semi-mechanistic-modeling-approach-to-support-phase-iii-dose-selection-for-tak-875-integrating-glucose-and-hba1c-data/ 2017-12-27 https://lapp.nl/a-population-pk-pd-model-for-effects-of-sipoglitazar-on-fpg-and-hba1c-in-patients-with-type-ii-diabetes/ 2017-12-27 https://lapp.nl/towards-the-prediction-of-cardiovascular-effects-in-human/ 2017-12-27 https://lapp.nl/population-modeling-of-blood-pressure-assessing-clinically-important-factors-for-cardiovascular-diseases/ 2017-12-27 https://lapp.nl/a-systems-pharmacology-model-of-the-app-processing-pathway-in-alzheimers-disease/ 2017-12-27 https://lapp.nl/development-of-a-dosing-regimen-for-recombinant-human-antithrombin-rhat-in-pregnant-patients/ 2025-12-05 https://lapp.nl/a-phase-2-safety-and-tolerability-study-to-investigate-the-effect-of-azd5213-on-sleep/ 2017-12-27 https://lapp.nl/gap-identification-as-a-critical-step-to-enable-integrated-clinical-trial-simulation-platforms/ 2017-12-27 https://lapp.nl/cap-identification-as-a-critical-step-to-enable-integrated-clinical-trial-simultaion-platforms/ 2017-12-27 https://lapp.nl/pharmacokinetic-pharmacodynamic-modeling-of-the-antihypertensive-effect-of-eprosartan/ 2024-06-04 https://lapp.nl/the-impact-of-p-gp-functionality/ 2024-06-04 https://lapp.nl/characterisation-of-the-pharmacokinetics-of-ethinylestradiol-and-drospirenone/ 2024-06-04 https://lapp.nl/pkpd-modelling-of-the-interrelationship/ 2024-06-04 https://lapp.nl/evaluation-of-the-impact-of-ugt-polymorphism/ 2024-06-04 https://lapp.nl/nonlinear-mixed-effects-modeling-of-the-diurnal-blood-pressure-profile/ 2024-06-04 https://lapp.nl/a-model-based-approach-to-analyze-the-influence-of-ugt2b15/ 2024-06-04 https://lapp.nl/pharmacokinetics-of-recombinant-human-antithrombin/ 2025-12-05 https://lapp.nl/application-of-ms-for-bispecifics-in-early-discorvery/ 2023-11-21 https://lapp.nl/a-hidden-markov-model-to-assess-drug-induced-sleep-fragmentation/ 2017-12-27 https://lapp.nl/quantification-of-the-drug-effect-and-exploration-of-mechanism-of-action-of-two-nmda-channel-blockers/ 2017-12-27 https://lapp.nl/an-integrated-mechanistic-model/ 2017-12-27 https://lapp.nl/a-step-wise-analysis-of-multiple-biomarkers-drives-the-development-of-a-semi-mechanistic-comprehensive-model-application-to-modulation-of-amyloid-%ce%b2/ 2017-12-27 https://lapp.nl/data-transformation-procedure-to-improve-identifiability-of-efficacy-and-potency/ 2017-12-27 https://lapp.nl/development-of-a-mechanistic-based-model-for-neonatal-fc-receptor-recycling-to-design-human-serum-albumin-mutants-with-extended-half-lives/ 2017-12-27 https://lapp.nl/quantification-of-antidepressant-and-sedative-effect-of-two-nmda-channel-blockers/ 2017-12-27 https://lapp.nl/comparing-a-mechanistic-with-an-empirical-approach-to-assess-resistance-development-of-antibacterials-in-vitro/ 2017-12-27 https://lapp.nl/acute-dopamine-inhibition-challenge/ 2024-06-04 https://lapp.nl/regional-brain-distribution-kinetics-in-rats/ 2024-06-04 https://lapp.nl/evaluation-of-blood-brain-barrier-transport-and-cns-drug-metabolism/ 2024-06-04 https://lapp.nl/population-modeling-of-blood-pressure/ 2017-12-27 https://lapp.nl/quantitative-understanding-of-drug-effects-on-the-interrelationship-between-mean-arterial-blood-pressure-cardiac-output-and-total-peripheral-resistance/ 2017-12-27 https://lapp.nl/challenges-in-non-clinical-assessment-of-antisense-oligonucleotides/ 2017-12-27 https://lapp.nl/drug-induced-sleep-fragmentation/ 2024-06-04 https://lapp.nl/morphine-and-its-metabolites/ 2024-06-04 https://lapp.nl/predictive-performance-in-simulation-models-of-clinical-trials/ 2024-06-04 https://lapp.nl/effect-on-cyp3a4-activity/ 2024-06-04 https://lapp.nl/a-true-markov-model-for-sleep-disturbance/ 2017-12-27 https://lapp.nl/a-novel-integrated-rnai-viral-dynamics-systems-pharmacology-model/ 2017-12-27 https://lapp.nl/drug-effects-on-the-cardiovascular-system/ 2017-12-27 https://lapp.nl/a-population-pd-model-for-effects-of-the-cytostatic-drugs-irinotecan-and-temozolomide-on-rh18-rabdomyosarcoma-xenografts-in-mice/ 2017-12-27 https://lapp.nl/clinical-impact-of-genetic-polymorphisms-observed-in-the-pharmacokinetics-of-the-novel-ppar-agonist-sipoglitazar/ 2017-12-27 https://lapp.nl/assessment-of-the-potential-for-displacement-interactions-with-sugammadex/ 2023-11-21 https://lapp.nl/effect-of-altered-agp-plasma-binding/ 2024-06-04 https://lapp.nl/marginal-increase-of-sunitinib-exposure/ 2024-06-04 https://lapp.nl/estimation-of-binding-rate-constants/ 2017-12-27 https://lapp.nl/modeling-of-alpha-interferon-response/ 2024-06-04 https://lapp.nl/clinical-trial-simulation/ 2024-06-04 https://lapp.nl/pharmacokinetics-of-clindamycin-in-pregnant-women/ 2024-06-04 https://lapp.nl/static-allodynia-response-to-pregabalin-and-sildenafil/ 2024-06-04 https://lapp.nl/explaining-variability-in-ciclosporin-exposure/ 2023-11-21 https://lapp.nl/is-calcineurin-activity-useful-as-a-biomarker-to-optimize-cyclosporine-a-therapy-in-renal-transplant-recipients/ 2017-12-27 https://lapp.nl/towards-the-implementation-of-the-markov-property-into-a-continuous-time-transition-state-model-in-nonmem/ 2017-12-27 https://lapp.nl/modelling-non-linear-dose-dependent-absorption-profiles-after-oral-prolonged-release-formulations/ 2017-12-27 https://lapp.nl/safety-pharmacology-screening-using-a-standardized-population-pharmacokineticpharmacodynamic-modelling-approach/ 2017-12-27 https://lapp.nl/genotyped-versus-phenotyped-dosing-to-account-for-ugt-polymorphism-of-the-novel-ppar-agonist-sipoglitazar/ 2017-12-27 https://lapp.nl/pharmacokinetic-and-pharmacodynamic-modeling-of-the-novel-oral-direct-factor-xa-inhibitor-tak-442/ 2017-12-27 https://lapp.nl/pharmacokinetics-of-amoxicillin/ 2023-11-21 https://lapp.nl/morphine-glucuronidation/ 2024-06-04 https://lapp.nl/population-pharmacokinetic-model-of-the-pregabalin-sildenafil-interaction-in-rats/ 2024-06-04 https://lapp.nl/pharmacokinetics-of-a-granisetron-transdermal-system/ 2024-06-04 https://lapp.nl/effect-of-altered-agp-plasma-binding-on-heart-rate-changes/ 2024-06-04 https://lapp.nl/influence-of-plasma-protein-binding-on-pharmacodynamics/ 2024-06-04 https://lapp.nl/explaining-variability-in-tacrolimus-pharmacokinetics/ 2023-11-21 https://lapp.nl/reversal-of-neuromuscular-blockade/ 2023-11-21 https://lapp.nl/washout-and-delayed-start-designs-for-identifying-disease-modifying-effects/ 2024-06-04 https://lapp.nl/incorporating-receptor-theory/ 2024-06-04 https://lapp.nl/changes-in-gabaa-receptor-properties-in-amygdala-kindled-animals/ 2024-06-04 https://lapp.nl/a-mechanism-based-pharmacokinetic-model-describing-the-interaction-between-sugammadex-and-rocuronium-in-patients-with-normal-and-impaired-renal-function/ 2017-12-27 https://lapp.nl/implementing-receptor-theory-in-pk-pd-modeling/ 2017-12-27 https://lapp.nl/are-wash-out-designs-better-than-delayed-start-designs/ 2017-12-27 https://lapp.nl/assessment-of-the-use-of-complex-baseline-models-in-preclinical-safety-screening/ 2017-12-27 https://lapp.nl/pharmacokinetic-pharmacodynamic-modelling-of-fluvoxamine-5-ht-transporter-occupancy-in-rat-frontal-cortex/ 2024-06-04 https://lapp.nl/mechanistic-model-for-the-acute-effect-of-fluvoxamine-on-5-ht-and-5-hiaa-concentrations/ 2024-06-04 https://lapp.nl/pharmacokinetic-modeling-of-non-linear-brain-distribution-of-fluvoxamine-in-the-rat/ 2024-06-04 https://lapp.nl/amoxicillin-pharmacokinetics-in-pregnant-women/ 2024-06-04 https://lapp.nl/mechanism-based-pharmacodynamic-modeling-of-s-atenolol/ 2024-06-04 https://lapp.nl/the-influence-of-labour-on-the-pharmacokinetics-of-intravenously-administered-amoxicillin-in-pregnant-women/ 2024-06-04 https://lapp.nl/extensions-to-the-visual-predictive-check-to-facilitate-model-performance-evaluation/ 2024-06-04 https://lapp.nl/mechanism-based-pharmacokinetic-pharmacodynamic-pk-pd-modeling/ 2024-06-04 https://lapp.nl/pharmacokinetic-pharmacodynamic-modelling-of-the-eeg-effects-of-opioids/ 2024-06-04 https://lapp.nl/dose-prediction-of-tacrolimus-in-de-novo-kidney-transplant-patients-with-population-pharmacokinetic-modelling-including-genetic-polymorphisms/ 2017-12-27 https://lapp.nl/utility-of-a-mixed-effects-approach-to-defining-target-binding-rate-constants/ 2017-12-27 https://lapp.nl/disease-system-analysis-distinguishing-disease-status-from-disease-process/ 2017-12-27 https://lapp.nl/population-pk-pd-analysis-of-compound-x-to-find-appropriate-dosage-regimen-in-clinical-trial/ 2017-12-27 https://lapp.nl/mechanism-based-model-of-effect-of-co-administration-of-exogenous-testosterone-and-progestogens-on-the-hypogonadalaxis-in-men/ 2017-12-27 https://lapp.nl/circadian-rhythm-in-pharmacodynamics-and-its-influence-on-the-identification-of-treatment-effects/ 2017-12-27 https://lapp.nl/pharmacokinetic-pharmacodynamic-modelling-of-s-atenolol-in-rats/ 2024-06-04 https://lapp.nl/disease-severity-is-a-major-determinant-for-the-pharmacodynamics-of-propofol-in-critically-ill-patients/ 2024-06-04 https://lapp.nl/pharmacokinetics-of-penicillin-g-in-infants/ 2024-06-04 https://lapp.nl/application-of-the-convection-dispersion-equation-to-modelling-oral-drug-absorption/ 2024-06-04 https://lapp.nl/mechanism-based-pharmacokinetic-pharmacodynamic-modeling/ 2024-06-04 https://lapp.nl/population-pharmacokinetic-model-of-fluvoxamine-in-rats/ 2024-06-04 https://lapp.nl/pharmacokinetic-pharmacodynamic-modeling-of-the-effect-of-fluvoxamine-on-p-chloroamphetamine-induced-behavior/ 2024-06-04 https://lapp.nl/population-pharmacokinetic-modelling-of-non-linear-brain-distribution-of-morphine/ 2024-06-04 https://lapp.nl/influence-of-biophase-distribution-and-p-glycoprotein-interaction/ 2024-06-04 https://lapp.nl/accurate-interpretation-of-the-visual-predictive-check-in-order-to-evaluate-model-performance/ 2017-12-27 https://lapp.nl/disease-system-analysis-distinguishing-disease-status-from-disease-process-2/ 2017-12-27 https://lapp.nl/propofol-pharmacokinetics-and-pharmacodynamics-for-depth-of-sedation/ 2024-06-04 https://lapp.nl/pharmacokinetics-and-pharmacodynamics-of-midazolam-and-metabolites/ 2024-06-04 https://lapp.nl/population-pharmacodynamic-modelling-of-lorazepam-and-midazolam-induced-sedation-upon-long-term-continuous-infusion-in-critically-ill-patients/ 2024-06-04 https://lapp.nl/long-term-effects-of-pioglitazone-metformin-and-gliclazide/ 2024-06-04 https://lapp.nl/treatment-efficacy-of-combination-therapy/ 2017-12-27 https://lapp.nl/robust-fitting-of-pharmacokinetic-models-to-phase-ii-iii-clinical-trial-data/ 2017-12-27 https://lapp.nl/mechanistic-disease-progression-analysis-indicates-that-pioglitazone-improves-s-cell-function-in-treatment-naive-type-2-diabetics/ 2017-12-27 https://lapp.nl/treatment-efficacy-of-pioglitazone-in-combination-therapy/ 2017-12-27 https://lapp.nl/cascading-disease-progression-analysis-in-type-2-diabetes/ 2017-12-27 https://lapp.nl/treatment-efficacy-of-combination-therapy-2/ 2017-12-27 https://lapp.nl/pharmacokinetic-pharmacodynamic-modelling-of-the-anti-hyperalgesic-and-anti-nociceptive-effect-of-adenosine-a1-receptor/ 2024-06-04 https://lapp.nl/population-pharmacokinetics-of-lorazepam-and-midazolam-and-their-metabolites-in-intensive-care-patients/ 2024-06-04 https://lapp.nl/basic-disease-progression-models-in-degenerative-disease/ 2024-06-04 https://lapp.nl/population-pharmacokinetic-analysis-for-simultaneous-determination-of-b-max-and-k-d-in-vivo/ 2024-06-04 https://lapp.nl/mechanistic-disease-progression-model-for-type-2-diabetes-mellitus-and-pioglitazone-treatment-effects/ 2017-12-27 https://lapp.nl/reversal-of-rocuronium-induced-neuromuscular-block-by-cyclodextin-org-25969/ 2017-12-27 https://lapp.nl/development-of-a-mechanism-based-pk-pd-model-of-the-reversal-of-rocuronium-induced-neuromuscular-block-by-org25969/ 2017-12-27 https://lapp.nl/disease-progression-analysis-for-type-2-diabetes-mellitus/ 2017-12-27 https://lapp.nl/towards-a-mechanistic-disease-progression-model-for-type-2-diabetes-mellitus/ 2017-12-27 https://lapp.nl/pk-pd-modelling-of-reversal-of-neuromuscular-by-a-chemically-optimised-cyclodextrin/ 2017-12-27 https://lapp.nl/absorption-model-based-on-transport-physics-theory-applied-to-paracetamol/ 2017-12-27 https://lapp.nl/mechanistic-disease-progression-analysis-indicates-that-pioglitazone-prevents-the-progression-of-t2dm/ 2017-12-27 https://lapp.nl/application-of-population-pharmacokinetic-analysis-for-quantification-of-in-vivo-binding-properties-in-the-rat-brain/ 2017-12-27 https://lapp.nl/mechanistic-disease-progression-analysis/ 2017-12-27 https://lapp.nl/integrating-multiple-biomarker-into-a-single-mechanistic-model-cascade-of-disease-processes/ 2017-12-27 https://lapp.nl/comparative-population-pharmacokinetics-of-lorazepam-and-midazolam-during-long-term-continuous-infusion-in-critically-ill-patients/ 2024-06-04 https://lapp.nl/population-pharmacokinetic-modeling-of-blood-brain-barrier-transport-of-synthetic-adenosine-a1-receptor-agonists/ 2024-06-04 https://lapp.nl/population-pharmacokinetic-pharmacodynamic-modelling-of-the-anti-hyperalgesic-effect-of-5deoxy-n6-cylopentyladenosine/ 2024-06-04 https://lapp.nl/modelling-of-drug-absorption-as-a-transport-proces-limited/ 2017-12-27 https://lapp.nl/extrapolation-of-pharmacokinetics-and-toxicity-from-pre-clinical-data-to-humans/ 2017-12-27 https://lapp.nl/population-pharmacokinetic-and-pharmacodynamic-modeling-of-propofol-for-long-term-sedation-in-critically-ill-patients/ 2024-06-04